Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 9, 2026

/C O R R E C T I O N -- Eli Lilly and Company/

View original at finance.yahoo.com

/C O R R E C T I O N -- Eli Lilly and Company/ In the news release, Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment, issued July 9, 2026 by Eli Lilly and Company over PR Newswire, we are advised by the comp…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Blood biomarker tests and amyloid PET agents are not currently indicated for use in cognitively unimpaired individuals, but the new results support a potentially scalable, accessible alternative to specialized imaging in the future.
60% confidence
Lilly's research at AAIC 2026 spans diagnostics, long-term treatment, disease biology, and patient-centered outcomes, reflecting its 35-year commitment to Alzheimer's disease science.
60% confidence
Eli Lilly and Company will present 16 abstracts at the 2026 Alzheimer's Association International Conference (AAIC), July 12-15 in London.
60% confidence
P-tau217 blood biomarker assays demonstrated strong rule-in performance comparable to amyloid PET for identifying Alzheimer's disease pathology in cognitively unimpaired individuals.
60% confidence

Data points we hold from this source

Eli Lilly and Company · years of alzheimers research commitment	35 years
Eli Lilly and Company · oral presentations	3 count
Eli Lilly and Company · poster presentations	13 count
Eli Lilly and Company · abstracts presented	16 count